A Noninvasive Ultrasound Based Technique to Identify Treatment Responders in Patients with Portal Hypertension.
A Noninvasive Ultrasound Based Technique to Identify Treatment Responders in Patients with Portal Hypertension.
复制标题
DOI：
10.1016/j.acra.2020.11.023
复制
发表时间：
2021-11
影响因子：
4.8
通讯作者：
Forsberg F
中科院分区：
文献类型：
--
作者：
Gupta I;Fenkel JM;Eisenbrey JR;Machado P;Stanczak M;Wessner CE;Shaw CM;Miller C;Soulen MC;Wallace K;Forsberg F
次谐波辅助压力估计（SHAPE）是基于超声造影剂微泡的次谐波幅度与环境压力之间的反比关系。本研究的目的是验证SHAPE是否可以准确监测门脉高压患者的疾病进展。使用Sonazoid（GE Healthcare，奥斯陆，挪威; IND 124，465），使用带有4C曲线-线性探头的改良Logiq 9扫描仪（GE，沃基沙，WI）采集SHAPE数据（在2.5/1.25 MHz下发送/接收）。根据肝静脉压力梯度（HVPG）结果（即，HVPG ≥ 10 mmHg）。每6.2个月重复进行一次SHAPE检查。肝功能检查和临床指标用于确定治疗反应。在21例门脉高压症患者中，11例成功随访，平均随访时间为6.2个月。与单一无应答者（2.33 dB; p < 0.001）相比，被归类为治疗应答者（n=10;-4.01 ±3.61 dB）的组中SHAPE信号降低显著更大。应答者的结果与改善的终末期肝病模型（MELD）评分、门静脉高压的根本原因改善、肝功能检查改善和腹水减少的相应临床结局相匹配。SHAPE可以潜在地监测门静脉高压症患者的疾病进展，因此，可能有助于临床医生对患者的管理。一项更大规模的研究将进一步证实这一说法。
Subharmonic aided pressure estimation (SHAPE) is based on the inverse relationship between the subharmonic amplitude of ultrasound contrast microbubbles and ambient pressure. The aim of this study was to verify if SHAPE can accurately monitor disease progression in patients identified with portal hypertension. A modified Logiq 9 scanner with a 4C curvi-linear probe (GE, Waukesha, WI) was used to acquire SHAPE data (transmitting/receiving at 2.5/1.25MHz) using Sonazoid (GE Healthcare, Oslo, Norway; IND 124,465). Twenty-one (median age 59 years; 12 Males) of the 178 patients enrolled in this IRB approved study (14F.113) were identified as having clinically significant portal hypertension based on their hepatic venous pressure gradient (HVPG) results (i.e., HVPG ≥ 10 mmHg). Repeat SHAPE examinations were done every 6.2 months. Liver function tests and clinical indicators were used to establish treatment response. Of the 21 portal hypertensive subjects, 11 had successful follow up scans with an average follow up time of 6.2 months. There was a significantly larger SHAPE signal reduction in the group who were classified as treatment responders (n=10; −4.01±3.61 dB) compared to the single non-responder (2.33 dB; p < 0.001). Results for responders matched the corresponding clinical outcomes of improved Model for End Stage Liver Disease (MELD) scores, improvement in underlying cause of portal hypertension, improved liver function tests and reduced ascites. SHAPE can potentially monitor disease progression in portal hypertensive patients and hence, may help clinicians in patient management. A larger study would further validate this claim.
登录
查看更多内容
影响因子：
19.7
作者：
Gupta, Ipshita;Eisenbrey, John R.;Forsberg, Flemming
通讯作者：
Forsberg, Flemming
DOI：
10.1016/j.jcmg.2011.08.017
发表时间：
2012-01
期刊：
JACC. Cardiovascular imaging
影响因子：
--
作者：
Dave JK;Halldorsdottir VG;Eisenbrey JR;Raichlen JS;Liu JB;McDonald ME;Dickie K;Wang S;Leung C;Forsberg F
通讯作者：
Forsberg F
影响因子：
2.3
作者：
Halldorsdottir VG;Dave JK;Leodore LM;Eisenbrey JR;Park S;Hall AL;Thomenius K;Forsberg F
通讯作者：
Forsberg F
影响因子：
2.9
作者：
Shi, WT;Forsberg, F;Goldberg, BB
通讯作者：
Goldberg, BB
影响因子：
2.3
作者：
Forsberg, F;Liu, JB;Hall, AL
通讯作者：
Hall, AL